NTLA
Intellia Therapeutics, Inc
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Best Diagnostics Stocks 2026 →
Intellia Therapeutics (NTLA) Stock: Buy, Sell, or Hold?
$11.17
-0.94 (-7.76%)
▼
5d:
-5.82%
30d:
-11.21%
90d:
-7.61%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 05, 2026
0d
Protect NTLA Gains
Updated Nov 10, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (53%)
Quality Score
46/100
Position
OVERSOLD
30-Day Fair Range
$11.32 – $12.61
Position: OVERSOLD
Forward P/E & Valuation
-4.3x
Next 12M consensus est.
Wall Street Target
$22.78
+103.9% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$10.87 / $13.94
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: NTLA shows conflicting indicators. Wait for confirmation before entering.
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Nov 2, 2026 at $11.96 · last confirmed Nov 9, 2026
Strength: 5.6/10
Get Alerted When NTLA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: NTLA is currently trading at $11.17, which is considered oversold relative to its 30-day fair value range of $11.32 to $12.61.
Technical Outlook: Technically, NTLA is in a downtrend. The price is currently testing key support at $10.87. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.8% recently.
Market Sentiment: NTLA scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.78 (+103.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NTLA is in a downtrend. The price is currently testing key support at $10.87. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.8% recently.
Market Sentiment: NTLA scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.78 (+103.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$11.32 -
$12.61
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
Trading Range & Key Levels
30-Day Trading Range
$11.32 -
$12.61
Current vs Trading Range
OVERSOLD
Support Level
$10.87
Resistance Level
$13.94
Current Trend
Downtrend
Technical data as of
Nov 10, 2026
Protect Your Profits
Holding NTLA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (34/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.8%)
- BULLISH: Trading 103.9% below Wall St target ($22.78)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-4.25
Wall Street Target
$22.78
(+103.9%)
Revenue Growth (YoY)
-48.0%
Share NTLA Analysis
Share this live NTLA analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (NTLA)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
Intellia Therapeutics is presenting at the Jefferies Global Healthcare Conference in London on November 17, 2026.
Key Retail Themes:
Company presentation at a healthcare conference
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 5:06 AM ET
Data refreshes hourly during market hours. Next update: 6:06 AM
Data refreshes hourly during market hours. Next update: 6:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NTLA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 47 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 31 SELL |
|
BNTX
BioNTech SE |
BUY
21 analysts |
$114 | 63 BUY |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 43 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
Advanced NTLA Option Strategies
Professional options setups generated by AI based on today's NTLA price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive NTLA Research Pages
